Kibow Biotech, a developer of probiotic dietary supplements for kidney health, announced on Thursday the availability of its flagship product, Renadyl, in Canada.
Developed through decades of research into the relationship between gut health and kidney function, Renadyl is a patented, clinically studied probiotic supplement scientifically formulated to help maintain healthy kidney function. Its unique approach focuses on the gut microbiome and its role in managing certain waste compounds that can place additional demands on the kidneys.
According to Kibow, Renadyl features a proprietary blend of three probiotic strains delivering 45 billion colony-forming units (CFUs) per daily serving. Designed to work within the intestinal environment, these beneficial bacteria help support the body's natural processes for managing certain waste compounds while promoting a healthier gut environment.
Anixa Biosciences and Curia to finalise formulation of breast cancer vaccine for Phase 2 trial
Akagera Medicines receives Gates Foundation grant expansion to advance tuberculosis vaccine
Ten63 Therapeutics launches BEYOND-Alpha early adopter programme
Eloxx Pharmaceuticals publishes Phase 2a exaluren data in nonsense mutation Alport syndrome
Bristol Myers Squibb reports first Phase 3 data for KarXT in Alzheimer's-related psychosis
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Dicot Pharma initiates phase 2b clinical study of erectile dysfunction drug candidate
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Rakuten Medical launches Phase 1 first-in-human trial of PD-L1-targeted RM-0256 photoimmunotherapy
BioArctic and Eisai report positive five-year data for Leqembi in early Alzheimer's disease
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer